118 related articles for article (PubMed ID: 30127038)
1. Androgen deprivation therapy for metastatic salivary gland cancer.
Elkrief A; Saleh R
CMAJ; 2018 Aug; 190(33):E985-E987. PubMed ID: 30127038
[No Abstract] [Full Text] [Related]
2. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.
Locati LD; Perrone F; Cortelazzi B; Lo Vullo S; Bossi P; Dagrada G; Quattrone P; Bergamini C; Potepan P; Civelli E; Fallai C; Pilotti S; Licitra L
Head Neck; 2016 May; 38(5):724-31. PubMed ID: 25522335
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
Boon E; van Boxtel W; Buter J; Baatenburg de Jong RJ; van Es RJJ; Bel M; Fiets E; Oosting SF; Slingerland M; Hoeben A; Tesselaar MET; Jonker MA; Flucke UE; ; van der Graaf WTA; van Herpen CML
Head Neck; 2018 Mar; 40(3):605-613. PubMed ID: 29272069
[TBL] [Abstract][Full Text] [Related]
4. [Effective treatment by both anti-androgen therapy and chemotherapy for a patient with advanced salivary duct carcinoma].
Kuroda H; Sakurai T; Yamada M; Uemura N; Ono M; Abe T; Fujii S; Maeda M; Kohda K; Obata M; Ando M; Iyama S; Kato J
Gan To Kagaku Ryoho; 2011 Apr; 38(4):627-30. PubMed ID: 21498992
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone in metastatic salivary duct carcinoma.
Urban D; Rischin D; Angel C; D'Costa I; Solomon B
J Natl Compr Canc Netw; 2015 Mar; 13(3):288-90. PubMed ID: 25736005
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
Yamamoto N; Minami S; Fujii M
Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467
[TBL] [Abstract][Full Text] [Related]
7. Combined androgen blockade for salivary gland carcinoma.
Gourd E
Lancet Oncol; 2018 Jan; 19(1):e17. PubMed ID: 29233558
[No Abstract] [Full Text] [Related]
8. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy.
Soper MS; Iganej S; Thompson LD
Head Neck; 2014 Jan; 36(1):E4-7. PubMed ID: 23720164
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
Jaspers HC; Verbist BM; Schoffelen R; Mattijssen V; Slootweg PJ; van der Graaf WT; van Herpen CM
J Clin Oncol; 2011 Jun; 29(16):e473-6. PubMed ID: 21422415
[No Abstract] [Full Text] [Related]
10. Blockade of Androgen-induced Malignant Phenotypes by Flutamide Administration in Human Salivary Duct Carcinoma Cells.
Kamata YU; Sumida T; Murase R; Nakano H; Yamada T; Mori Y
Anticancer Res; 2016 Nov; 36(11):6071-6075. PubMed ID: 27793934
[TBL] [Abstract][Full Text] [Related]
11. Update and perspectives on non-surgical treatment of salivary gland malignancies.
Airoldi M; Cortesina G; Giordano C; Pedani F; Cavalot A; Marcato P; Beatrice F; Bumma C
Acta Otorhinolaryngol Ital; 2003 Oct; 23(5):368-76. PubMed ID: 15108487
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?
Alfieri S; Granata R; Bergamini C; Resteghini C; Bossi P; Licitra LF; Locati LD
Oral Oncol; 2017 Mar; 66():58-63. PubMed ID: 28249649
[TBL] [Abstract][Full Text] [Related]
13. Management of the side effects of androgen deprivation therapy in men with prostate cancer.
Flaig TW; Glodé LM
Expert Opin Pharmacother; 2008 Nov; 9(16):2829-41. PubMed ID: 18937615
[TBL] [Abstract][Full Text] [Related]
14. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck.
Hong MH; Kim CG; Koh YW; Choi EC; Kim J; Yoon SO; Kim HR; Cho BC
Head Neck; 2018 Jan; 40(1):55-62. PubMed ID: 29044862
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy for prostate cancer.
Das M
Lancet Oncol; 2017 Oct; 18(10):e567. PubMed ID: 28870614
[No Abstract] [Full Text] [Related]
17. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
18. Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients.
De Block K; Vander Poorten V; Dormaar T; Nuyts S; Hauben E; Floris G; Deroose CM; Schöffski P; Clement PM
Acta Clin Belg; 2016 Dec; 71(6):383-388. PubMed ID: 27285571
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy combined with androgen-deprivation therapy in high-volume metastatic hormone sensitive prostate cancer: a short-term efficacy and safety analysis].
Xu PH; Shen YJ; Xiao WJ; Lin GW; Qin XJ; Zhu Y; Dai B; Ye DW
Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):418-421. PubMed ID: 31142065
[No Abstract] [Full Text] [Related]
20. [Role of androgen in the elderly. Problems of androgen deprivation therapy].
Tsujimura A
Clin Calcium; 2013 Aug; 23(8):1185-90. PubMed ID: 23892220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
